Volume 5, Issue 1 (Spring & summer 2017 2017)                   Jorjani Biomed J 2017, 5(1): 14-24 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

BaghbanRahimi S, Soleimanjahi H, Mohebbi A, Ebrahimzadeh M S, Alizade L, Ghaemi A. Evaluation of DNA vaccine encoding HPV-16 E7 on Lymphocyte proliferation induction in Human Papilloma Virus-associated tumor animal models. Jorjani Biomed J. 2017; 5 (1) :14-24
URL: http://goums.ac.ir/jorjanijournal/article-1-528-en.html
1- Department of Microbiology, Golestan University of Medical Sciences, Gorgan, Iran
2- Department of Virology, Tarbiat Modares University, Tehran, Iran
3- Department of Microbiology, Golestan University of Medical Sciences, Gorgan, Iran.
4- Shefa Neuroscience Research Center, Khatam Al-Anbiya Hospital, Tehran, Iran
5- Department of Microbiology, Golestan University of Medical Sciences, Gorgan, Iran , Ghaem_amir@yahoo.com
Abstract:   (2457 Views)
Background & Objective: Human papillomavirus (HPV) oncoproteins, including E6 and E7 are constitutively expressed in cervical cancer cells. These proteins are ideal targets to be used for developing therapeutic vaccines against existing HPV-associated carcinomas. The aim of this study was to measure the proliferation response rate of splenic lymphocytes derived from E7-HPV16 encoding plasmid injection on the tumor mouse model of papillomavirus.
Method: C57BL/6 mice were inoculated subcutaneous with 5× 10⁵ TC-1 cells in three times with two weeks intervals and then immunized with HPV-16 E7 DNA vaccine. The proliferation response of splenic cells was measured by MTT assay. IL12 cytokine was measured by ELISA assay and the mass of tumor was calculated with caliper for six weeks.
Results: Following the application of DNA vaccines containing E7 therapeutic gene, the proliferative response of splenic cells was provoked significanltly higher than the stimulation in control group (P<0.05). Moreover, the secretion of IL12 was significantly increased in vaccinated mice tumor tissue (P<0.05). The growth of tumor in vaccinated group was markedly decreased in comparison to PBS and pcDNA3 groups (P<0.05).
Conclusion: Our findings revealed that the application of DNA vaccine containing E7 gene in a tumor mouse model may induce anti-tumor cellular immune responses.
Full-Text [PDF 905 kb]   (955 Downloads)    
Type of Article: Original article | Subject: General medicine
Received: 2017/09/27 | Revised: 2017/11/8 | Accepted: 2017/09/27

1. Broomall EM, Reynolds SM, Jacobson RM. Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus. Postgraduate medicine. 2010;122(2):121-9 [Article]
2. WHO/ICO. HPV Information Centre Human papillomavirus and related cancers in world. Summary Report WHO. (2010) [Article]
3. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine. 2003;348(6):518-27 [Article]
4. Cho H, Lee H-J, Heo Y-K, Cho Y, Gwon Y-D, Kim M-G, et al. Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine. PloS one. 2014;9(4):e95961 [Article]
5. McLaughlin-Drubin ME, Münger K. The human papillomavirus E7 oncoprotein. Virology. 2009;384(2):335-44 [Article]
6. Zur Hausen H. Papillomavirus infections—a major cause of human cancers. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 1996;1288(2):F55-F78 [Article]
7. Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus genes. 2010;40(1):1-13 [Article]
8. Tahamtan A, Tabarraei A, Moradi A, Dinarvand M, Kelishadi M, Ghaemi A, et al. Chitosan nanoparticles as a potential nonviral gene delivery for HPV-16 E7 into mammalian cells. Artificial cells, nanomedicine, and biotechnology. 2014(0):1-7 [Article]
9. Sajadian A, Tabarraei A, Soleimanjahi H, Fotouhi F, Gorji A, Ghaemi A. Comparing the effect of Toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine. Archives of virology. 2014;159(8):1951-60 [Article]
10. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. Journal of the National Cancer Institute. 1995;87(11):796-802 [Article]
11. McIntosh J, Sturpe DA, Khanna N. Human papillomavirus vaccine and cervical cancer prevention: Practice and policy implications for pharmacists. Journal of the American Pharmacists Association. 2008;48(1):e1-e17 [Article]
12. Syrjänen KJ, Syrjänen SM. Papillomavirus infections in human pathology: Wiley; 2000 [Article]
13. Ghaemi A, Soleimanjahi H, Gill P, Hassan Z, Jahromi SRM, Roohvand F. Research Recombinant λ-phage nanobioparticles for tumor therapy in mice models. 2010 [Article]
14. Cohen SN, Chang AC, Boyer HW, Helling RB. Construction of biologically functional bacterial plasmids in vitro. Proceedings of the National Academy of Sciences. 1973;70(11):3240-4 [Article]
15. Ghaemi A, Soleimanjahi H, Gill P, Hassan ZM, Razeghi S, Fazeli M, et al. Protection of mice by a λ-based therapeutic vaccine against cancer associated with human papillomavirus type 16. Intervirology. 2010;54(3):105-12 [Article]
16. Gableh F, Saeidi M, Hemati S, Hamdi K, Soleimanjahi H, Gorji A, et al. Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine. Journal of biomedical science. 2016;23(1):1 [Article]
17. Howley PM. Fields virology: Lippincott, Williams & Wilkins; 2013 [Article]
18. Palmer KE, Jenson AB, Kouokam JC, Lasnik AB, Ghim S-j. Recombinant vaccines for the prevention of human papillomavirus infection and cervical cancer. Experimental and molecular pathology. 2009;86(3):224-33 [Article]
19. Hsieh C-S, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science. 1993;260(5107):547-9 [Article]
20. Kaliński P, Hilkens C, Snijders A, Snijdewint F, Kapsenberg ML. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. The Journal of Immunology. 1997;159(1):28-35 [Article]
21. Wang KS, Frank DA, Ritz J. Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood. 2000;95(10):3183-90 [Article]

Add your comments about this article : Your username or Email:

Send email to the article author

© 2020 All Rights Reserved | Jorjani Biomedicine Journal

Designed & Developed by : Yektaweb